{"analyses":[{"ciLowerLimit":"5.1","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"26.8","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Response rate","paramValue":"6"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"PR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be \\<10 mm in the short axis.) or partial reponse (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters \\[e.g., percent change from Baseline\\]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per RECIST, version 1.1.","groups":[{"description":"Participants who received dabrafenib 150 mg capsules BID alone in the Randomized Phase were given the opportunity to receive combination dosing of dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD upon disease progression with approval of the GlaxoSmithKline (GSK) Medical Monitor.","id":"OG000","title":"Part C (Crossover): Dabrafenib 150 mg + Trametinib 2 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Crossover Population: participants who were randomized to and received at least one dose of dabrafenib monotherapy, and who elected to crossover to combination therapy following disease progression while on monotherapy","reportingStatus":"POSTED","timeFrame":"From the first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 7 years)","title":"Part C (Crossover): Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response as Assessed by the Investigator","type":"PRIMARY","unitOfMeasure":"Participants"}